Sales of Aduhelm, Biogen’s remedy for Alzheimer’s illness, continued to underperform expectations within the fourth quarter, Biogen stated Thursday, main the corporate to subject a disappointing monetary forecast for 2022.
Aduhelm accounted for $1 million in income within the ultimate three months of 2021, depressed by continued doubts concerning the drug’s profit for sufferers and restrictions positioned on its use by insurance coverage firms. Analysts who cowl Biogen had been anticipating the corporate to ship $2 million in Aduhelm gross sales throughout the fourth quarter.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
What’s it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, coverage, and life science protection and evaluation.
Our award-winning workforce covers information on Wall Road, coverage developments in Washington, early science breakthroughs and medical trial outcomes, and well being care disruption in Silicon Valley and past.
What’s included?
- Every day reporting and evaluation
- Essentially the most complete trade protection from a powerhouse workforce of reporters
- Subscriber-only newsletters
- Every day newsletters to temporary you on an important trade information of the day
- STAT+ Conversations
- Weekly alternatives to have interaction with our reporters and main trade consultants in reside video conversations
- Unique trade occasions
- Premium entry to subscriber-only networking occasions across the nation
- The most effective reporters within the trade
- Essentially the most trusted and well-connected newsroom within the well being care trade
- And rather more
- Unique interviews with trade leaders, profiles, and premium instruments, like our CRISPR Trackr.
